All Stories

  1. Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis

    Article • European Respiratory Journal, April 2021, European Respiratory Society (ERS)

    Shashikant Srivastava

  2. Nouveau short-course therapy and morphism mapping for clinical pulmonary Mycobacterium kansasii

    Article • Antimicrobial Agents and Chemotherapy, February 2021, ASM Journals

    Shashikant Srivastava

  3. Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis

    Article • Frontiers in Pharmacology, January 2021, Frontiers

    Shashikant Srivastava

  4. Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children

    Article • The Pediatric Infectious Disease Journal, August 2020, Wolters Kluwer Health

    Shashikant Srivastava

  5. Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii

    Article • Antimicrobial Agents and Chemotherapy, July 2020, ASM Journals

    Shashikant Srivastava

  6. Effect of specimen processing, growth supplement, and different metabolic population on Mycobacterium tuberculosis laboratory diagnosis

    Article • PLoS ONE, April 2020, PLOS

    Shashikant Srivastava

  7. Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill

    Article • Journal of Antimicrobial Chemotherapy, February 2020, Oxford University Press (OUP)

    Shashikant Srivastava

  8. A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live BCG

    Article • American Journal of Respiratory and Critical Care Medicine, December 2019, American Thoracic Society

    Shashikant Srivastava

  9. Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis

    Article • American Journal of Respiratory and Critical Care Medicine, November 2018, American Thoracic Society

    Dr Tawanda Gumbo, Shashikant Srivastava

  10. Clofazimine for the Treatment of Mycobacterium kansasii

    Article • Antimicrobial Agents and Chemotherapy, May 2018, ASM Journals

    Shashikant Srivastava

  11. Reply to Zimenkov, “Mutation in luxR Family Transcriptional Regulator Rv0890c Is Not a Marker of Linezolid Resistance”

    Article • Antimicrobial Agents and Chemotherapy, February 2018, ASM Journals

    Dr Tawanda Gumbo, Shashikant Srivastava

  12. A ‘shock and awe’ thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium–intracellulare complex disease

    Article • Journal of Antimicrobial Chemotherapy, September 2017, Oxford University Press (OUP)

    Shashikant Srivastava

  13. A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting

    Article • Journal of Antimicrobial Chemotherapy, September 2017, Oxford University Press (OUP)

    Shashikant Srivastava

  14. Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease

    Article • Journal of Antimicrobial Chemotherapy, September 2017, Oxford University Press (OUP)

    Shashikant Srivastava

  15. Linezolid as treatment for pulmonary Mycobacterium avium disease

    Article • Journal of Antimicrobial Chemotherapy, September 2017, Oxford University Press (OUP)

    Shashikant Srivastava

  16. A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease

    Article • Journal of Antimicrobial Chemotherapy, September 2017, Oxford University Press (OUP)

    Shashikant Srivastava

  17. Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium–intracellulare complex disease

    Article • Journal of Antimicrobial Chemotherapy, September 2017, Oxford University Press (OUP)

    Shashikant Srivastava

  18. Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance

    Article • Journal of Antimicrobial Chemotherapy, September 2017, Oxford University Press (OUP)

    Shashikant Srivastava

  19. The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent

    Article • Journal of Antimicrobial Chemotherapy, September 2017, Oxford University Press (OUP)

    Shashikant Srivastava

  20. pH Conditions under Which Pyrazinamide Works in Humans

    Article • Antimicrobial Agents and Chemotherapy, August 2017, ASM Journals

    Dr Tawanda Gumbo, Shashikant Srivastava

  21. Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence

    Article • Antimicrobial Agents and Chemotherapy, August 2017, ASM Journals

    Dr Tawanda Gumbo, Shashikant Srivastava

  22. Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB

    Article • Journal of Antimicrobial Chemotherapy, May 2017, Oxford University Press (OUP)

    Shashikant Srivastava

  23. Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection

    Article • Antimicrobial Agents and Chemotherapy, July 2016, ASM Journals

    Dr Tawanda Gumbo, Shashikant Srivastava

  24. Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases

    Article • Antimicrobial Agents and Chemotherapy, May 2016, ASM Journals

    Dr Tawanda Gumbo, Shashikant Srivastava

  25. Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease

    Article • Antimicrobial Agents and Chemotherapy, April 2016, ASM Journals

    Dr Tawanda Gumbo, Shashikant Srivastava

  26. A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies

    Article • EBioMedicine, April 2016, Elsevier

    Shashikant Srivastava

  27. Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease

    Article • Antimicrobial Agents and Chemotherapy, February 2016, ASM Journals

    Dr Tawanda Gumbo, Shashikant Srivastava

  28. Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model

    Article • Antimicrobial Agents and Chemotherapy, December 2015, ASM Journals

    Shashikant Srivastava

  29. Rapid Drug Tolerance and Dramatic Sterilizing Effect of Moxifloxacin Monotherapy in a Novel Hollow-Fiber Model of Intracellular Mycobacterium kansasii Disease

    Article • Antimicrobial Agents and Chemotherapy, February 2015, ASM Journals

    Shashikant Srivastava

  30. Acquired Drug Resistance Because of Pharmacokinetic Variability in a Young Child With Tuberculosis

    Article • The Pediatric Infectious Disease Journal, November 2014, Wolters Kluwer Health

    Shashikant Srivastava

  31. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?

    Article • European Respiratory Journal, November 2013, European Respiratory Society (ERS)

    Shashikant Srivastava

  32. In vitrosusceptibility testing and totally drug-resistant tuberculosis

    Article • European Respiratory Journal, June 2013, European Respiratory Society (ERS)

    Shashikant Srivastava

  33. Scientific and patient care evidence to change susceptibility breakpoints for first-line anti-tuberculosis drugs [Correspondence]

    Article • The International Journal of Tuberculosis and Lung Disease, May 2012, International Union Against Tuberculosis and Lung Disease

    Shashikant Srivastava

  34. Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy

    Article • Clinical Infectious Diseases, March 2012, Oxford University Press (OUP)

    Shashikant Srivastava

  35. Reply to “Pharmacokinetic Mismatch of Tuberculosis Drugs”

    Article • Antimicrobial Agents and Chemotherapy, February 2012, ASM Journals

    Shashikant Srivastava

  36. Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability

    Article • The Journal of Infectious Diseases, October 2011, Oxford University Press (OUP)

    Shashikant Srivastava

  37. In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens

    Article • Current Pharmaceutical Design, September 2011, Bentham Science Publishers

    Shashikant Srivastava

  38. Moxifloxacin Pharmacokinetics/Pharmacodynamics and Optimal Dose and Susceptibility Breakpoint Identification for Treatment of Disseminated Mycobacterium avium Infection

    Article • Antimicrobial Agents and Chemotherapy, April 2010, ASM Journals

    Shashikant Srivastava